Last reviewed · How we verify
NCT04805788
Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer
Phase 2 trial testing Proton Stereotactic Body Radiation Therapy in Recurrent Hepatocellular Carcinoma in 9 participants. Terminated before completion.
15 February 2024
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 24 August 2021 |
| Primary completion | 15 February 2024 |
| Estimated completion | 28 January 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Proton Stereotactic Body Radiation Therapy
- Quality-of-Life Assessment
Conditions studied
- Recurrent Hepatocellular Carcinoma — all drugs for Recurrent Hepatocellular Carcinoma →
- Stage I Hepatocellular Carcinoma AJCC v8 — all drugs for Stage I Hepatocellular Carcinoma AJCC v8 →
- Stage II Hepatocellular Carcinoma AJCC v8 — all drugs for Stage II Hepatocellular Carcinoma AJCC v8 →
- Stage III Hepatocellular Carcinoma AJCC v8 — all drugs for Stage III Hepatocellular Carcinoma AJCC v8 →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Recurrent Hepatocellular Carcinoma or Stage I Hepatocellular Carcinoma AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies the effect of stereotactic body proton radiotherapy in treating patients with liver cancer. Proton radiotherapy is a type of treatment that uses high-energy beams to treat tumors.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences.
Hu Y, Zhao C, Ji R, Chen W, et al · · 2022 · cited 10× · PMID 39036452 · DOI 10.1016/j.jncc.2022.05.002 -
Do We Have a Winner? Advocating for SBRT in HCC Management.
Safavi AH, Dawson LA, Mesci A. · · 2024 · cited 6× · PMID 38380116 · DOI 10.1016/j.ctro.2024.100740 -
Proton therapy in the treatment of hepatocellular carcinoma.
Dionisi F, Scartoni D, Fracchiolla F, Giacomelli I, et al · · 2022 · cited 2× · PMID 36003769 · DOI 10.3389/fonc.2022.959552 -
Modern approach to hepatocellular carcinoma treatment.
Cortese F, Anagnostopoulos F, Bazzocchi MV, Caringi S, et al · · 2025 · cited 1× · PMID 40901598 · DOI 10.4254/wjh.v17.i8.107873
Verify or expand the search:
- PubMed search for NCT04805788
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06609850 — The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma · NA · recruiting
- NCT05103904 — Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant · Phase 2 · recruiting
- NCT04514484 — Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and · Phase 1 · active not recruiting
- NCT04851119 — Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors · Phase 1, PHASE2 · recruiting
- NCT04615143 — Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC · Phase 2 · recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04805788 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04805788.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing